BCL2 and cancer: M. A. Scully et al. developed a novel nanoplatform utilizing cancer cell membrane-wrapped poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CCNPs) for the targeted delivery of the Bcl-2 inhibitor ABT-737 [52].